LB206
/ Centessa
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 14, 2023
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
(GlobeNewswire)
- "Anticipated Upcoming Program Milestones...PD-L1xCD47 LockBody (LB101) - The Phase 1/2a first-in-human clinical study is ongoing. PD-L1xCD3 LockBody (LB206) - LB206 has been named as a development candidate."
New molecule • Trial status • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1